Gilead Reports Positive Late-Stage Study Results for Remdesivir in Patients With Moderate COVID-19
The company stated that patients receiving a 5-day course of treatment with remdesivir plus the standard of care were 65% more likely to experience clinical improvement at day 11 than patients receiving the standard of care alone. The results for remdesivir are encouraging in that they show that early intervention with remdesivir can help patients with moderate cases of COVID-19. Gilead previously announced positive results from another phase 3 study of the antiviral drug in patients with severe cases of the novel coronavirus.
